- Home
- »
- Biotechnology
- »
-
Multiomics-based Drug Discovery & Development: Emerging Opportunities & Competitive LandscapeGVR Report cover
Multiomics-based Drug Discovery And Development: Emerging Opportunities & Competitive Landscape
Report Overview
The drug discovery and development landscape is undergoing a paradigm shift, driven by the convergence of multiomics technologies including genomics, transcriptomics, proteomics, metabolomics, and epigenomics. These integrative approaches provide a comprehensive molecular understanding of disease biology, enabling the discovery of novel drug targets, predictive biomarkers, and patient stratification strategies with unprecedented precision.
Multiomics-based approaches are accelerating the transition from one-size-fits-all therapies to precision and systems medicine. Advances in next-generation sequencing (NGS), mass spectrometry, single-cell technologies, and computational biology have made it feasible to generate, integrate, and analyze large-scale omics datasets. When combined with AI and machine learning, multiomics can uncover complex biological networks and causal mechanisms that traditional methods often overlook.
While adoption is rapidly increasing, challenges remain in terms of data integration, standardization, clinical validation, and regulatory acceptance. Nonetheless, multiomics is attracting significant attention from pharmaceutical companies, biotech startups, and research consortia aiming to de-risk R&D pipelines and improve drug efficacy and safety profiles.
Application Insights
Multiomics is transforming every stage of the drug development value chain-from target identification to post-marketing surveillance. By integrating different omics layers, researchers can better understand disease heterogeneity and tailor therapeutic interventions accordingly.
Table 1: Key application areas for omics technologies
Application Area
Omics Technologies
Key Functions
Example Companies
Target Discovery
Genomics, Proteomics
Identification of disease-driving genes and proteins
Insitro, Verge Genomics
Biomarker Discovery
Transcriptomics, Metabolomics
Stratification of patient subgroups, prediction of drug response
SomaLogic, Caris Life Sciences
Mechanism of Action
Proteomics, Metabolomics
Unraveling biological pathways and drug mechanisms
Biognosys, Evotec
Clinical Trial Optimization
Multiomics + AI
Patient selection, toxicity prediction, responder analysis
Tempus, Owkin
Personalized Therapies
Genomics, Epigenomics
Tailored treatments based on individual molecular profiles
Foundation Medicine, Helix
Key Growth Areas
The evolution of multiomics is being driven by innovations in both wet lab and computational domains. As technologies mature, they are enabling deeper biological insights and more robust translational applications.
Technology
Key Benefit
Use Case Example
Notable Players
Single-cell Multiomics
High-resolution cellular insights
Tumor heterogeneity profiling
10x Genomics, Mission Bio
Spatial Transcriptomics
Spatial context of gene expression
Tumor microenvironment mapping
NanoString, Vizgen
AI-based Integration
Predictive disease modeling
Drug response prediction
Owkin, PathAI
Cloud-based Analysis Platforms
Scalable, collaborative analytics
Cross-institutional drug studies
DNAnexus, Lifebit
Metabolomics Platforms
Real-time metabolic profiling
Metabolic biomarkers
Metabolon, Nightingale Health
Commercialization Landscape
With multiomics entering clinical and translational research workflows, the commercial landscape is expanding rapidly. Several pharma companies are forming strategic partnerships with omics tech providers and bioinformatics firms to co-develop precision therapies and diagnostics.
-
Big Pharma Partnerships: Roche’s acquisition of Flatiron Health and Foundation Medicine reflects a strategic shift toward data-driven R&D. Similarly, Pfizer, Novartis, and Merck are investing in multiomics-based platforms to bolster oncology and rare disease pipelines.
-
Startup Activity: AI-native drug discovery startups like Insitro, Recursion, and Deep Genomics are integrating multiomics data from the outset, redefining early-stage R&D.
-
Research Collaborations: Initiatives like the UK Biobank and NIH's All of Us program are building massive multiomics datasets for population-scale drug discovery.
Competitive Analysis: Thermo Fisher Scientific, Inc.
Company Overview:
-
Headquarter: Massachusetts, U.S.
-
Establishment Year: 1956
-
Employee Strength: 125,000
-
Business Overview: Thermo Fisher Scientific, Inc. is a global leader in the life sciences and biotechnology industry, offering a comprehensive suite of products and services that empower researchers across the multiomics landscape including genomics, transcriptomics, proteomics, metabolomics, and epigenomics. The company plays a pivotal role in enabling multiomics-based drug discovery and precision medicine by providing advanced instrumentation, reagents, analytical platforms, and bioinformatics tools.
Its offerings in the multiomics market include:
-
Next-Generation Sequencing (NGS) systems (Ion Torrent platform)
-
Mass Spectrometry and Chromatography systems for proteomics and metabolomics
-
Microarray technologies, RNA-seq, and single-cell omics solutions
-
Cloud-based data analysis platforms (e.g., Thermo Fisher Connect)
-
Bioinformatics pipelines for multi-layered omics data integration
Thermo Fisher serves pharmaceutical and biotech firms, academic institutions, clinical research organizations, and government agencies working in target discovery, biomarker identification, clinical diagnostics, and patient stratification. With continuous innovation and acquisitions (e.g., PPD, Patheon), Thermo Fisher is strategically positioned to capitalize on the growing demand for integrated multiomics solutions in drug development pipelines.
SWOT Analysis
SWOT Analysis - Thermo Fisher Scientific, Inc.
Strengths
Weaknesses
- Market leadership in genomics, proteomics, and metabolomics technologies through advanced platforms (e.g., Orbitrap MS, Ion Torrent).
- Vertical integration across the drug development lifecycle, from discovery to manufacturing.
- High-cost infrastructure may limit adoption of high-end systems in emerging markets.
- Integration across omics data layers remains complex, with some limitations in end-to-end multiomics workflows.
Opportunities
Threats
- Expanding demand for precision medicine and systems biology approaches opens new revenue streams in pharma R&D.
- Strategic partnerships with hospitals, research consortia, and AI-driven drug discovery startups can accelerate adoption of multiomics-based workflows.
- Competition from specialized omics technology providers (e.g., Illumina in genomics, Bruker in proteomics).
- Data privacy regulations and lack of harmonized standards could slow market uptake of cloud-based multiomics platforms.
Financial Performance
Key Financials (Thermo Fisher Scientific, Inc.)
2024 (USD million
2023 (USD million)
2022 (USD million)
Revenue
42,879
42,857
44,915
Operating Income/Loss
7,338
6,859
8,393
EBIT/EBITA
7,037
6,298
7,835
Net Income/Loss
6,335
5,955
6,960
List of top 15 companies involved in multiomics-based drug discovery & development industry:
-
Thermo Fisher Scientific
-
Illumina
-
Bruker Corporation
-
Agilent Technologies
-
10x Genomics
-
SomaLogic
-
Nightingale Health
-
NanoString Technologies
-
Insitro
-
Verge Genomics
-
Recursion Pharmaceuticals
-
Owkin
-
Deep Genomics
-
Foundation Medicine
-
Caris Life Sciences
-
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.